- Received treatment with CSL222 in Study CSL222_2001 or Study CSL222_3001, and completed participation in Study CSL222_2001 or Study CSL222_3001 or at least 5 years have passed since receiving CSL222.
Hemophilia B
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
NCT05962398 | PHASE 3 | OBSERVATIONAL
The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222_2001 (NCT03489291) or CSL222_3001 (NCT03569891).
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Phoenix Childrens Hospital
Phoenix,Arizona,United States,85016
Arkansas Children's Hospital Pharmacology
Little Rock,Arkansas,United States,72202
Orthopaedic Institute for Children
Los Angeles,California,United States,90007
Children's Hospital of Los Angeles
Los Angeles,California,United States,90027
UC Davis Medical Center
Sacramento,California,United States,95817
University of California, San Diego (UCSD)
San Diego,California,United States,92121
University of Michigan Medical Center
Ann Arbor,Michigan,United States,48109
Amsterdam Universitair Medische Centra (UMC)
Amsterdam Zuidoost,Netherlands,1105AZ
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov